InvestorsHub Logo
Followers 7
Posts 234
Boards Moderated 0
Alias Born 08/18/2018

Re: ElSid18 post# 338905

Friday, 06/25/2021 2:27:17 PM

Friday, June 25, 2021 2:27:17 PM

Post# of 345830
How we going to have a whisper miss.......

We will beat on revenue and eps substantially.

I believe we've had to have gotten upfront money from this:

Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that it will serve as the commercial manufacturer for the humanized monoclonal antibody portion of ZYNLONTA™ (loncastuximab tesirine-lpyl), a recently approved cancer treatment developed by ADC Therapeutics SA (NYSE: ADCT). Avid has provided clinical manufacturing services to ADC Therapeutics to support development of the product since 2017 and will now expand its manufacturing relationship with ADC Therapeutics to include commercial manufacturing activities for ZYNLONTA.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News